Clinical Trial Detail

NCT ID NCT03770299
Title An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease (CheckMate 9TN)
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

lung non-small cell carcinoma

Therapies

Docetaxel

Nivolumab

Paclitaxel

Cisplatin

Carboplatin

Gemcitabine

Pemetrexed Disodium

Vinorelbine

Age Groups: adult senior

No variant requirements are available.